Media Highlights and Announcements
November 25, 2021
Artrya expands into the United Kingdom
This week, Artrya announced a commercialisation agreement with Eversana to expand business into the UK.
November 24, 2021
Australian AI Company Artrya Announces Major UK Commercialisation Partnership with Eversana
AI medical technology company Artrya Limited is announcing its partnership with leading global commercial services provider EVERSANA Life Sciences LLC.
November 15, 2021
Boreham’s Crucible: Breaking down ASX aspirant Artrya’s AI heart disease warning system
In this Stockhead article, Tim Boreham dives into Artrya as a company and shares his thoughts in the current $100M market valuation. He also speaks on Artya’s recent accomplishments as well as goals in the months and years to come.
November 09, 2021
UK preferred supplier status for Australian AI company Artrya
Artrya has been accepted onto the UK National Health Service Shared Business Services (NHS SBS) Framework as a supplier of artificial intelligence software and platforms.
November 09, 2021
How to invest in the Artrya IPO
With the latest capital raise once again oversubscribed, Artrya has worked diligently to accommodate as many applications as possible.
Artrya Salix has been accepted as an NHS supplier for artificial intelligence software.
November 08, 2021
Medtech Artrya breaks into UK market
Crawley-based Artrya has been shortlisted as a preferred supplier of AI Software by the UK Health Service for its heart disease detection program.
November 04, 2021
Cardiac imaging start-up Artrya raising $40m through an IPO
In this article, the Financial Review shares some information on our accomplishments, IPO and overall progress towards our goals.
After closing our initial public offering (IPO), the Motley Fool shares details on Artrya’s AI technology and how it could disrupt the detection of coronary artery disease for years to come.
October 26, 2021
From the heart: Pandemic no barrier for medtech’s ASX listing
Amid a biotech boom, see how Artrya, an aussie medtech company, is pioneering the detection and assessment of the underlying cause of heart attack.